SG11202110623PA - Liposomal formulations, and methods of using and preparing thereof - Google Patents

Liposomal formulations, and methods of using and preparing thereof

Info

Publication number
SG11202110623PA
SG11202110623PA SG11202110623PA SG11202110623PA SG11202110623PA SG 11202110623P A SG11202110623P A SG 11202110623PA SG 11202110623P A SG11202110623P A SG 11202110623PA SG 11202110623P A SG11202110623P A SG 11202110623PA SG 11202110623P A SG11202110623P A SG 11202110623PA
Authority
SG
Singapore
Prior art keywords
molar percent
composition
phospholipid
liposome
salt
Prior art date
Application number
SG11202110623PA
Other languages
English (en)
Inventor
Agnes Rafalko
Teppei Shirakura
Samuel Eric Greenberg
Original Assignee
Glycomine Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glycomine Inc filed Critical Glycomine Inc
Publication of SG11202110623PA publication Critical patent/SG11202110623PA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11202110623PA 2019-03-29 2020-03-27 Liposomal formulations, and methods of using and preparing thereof SG11202110623PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962826874P 2019-03-29 2019-03-29
PCT/US2020/025246 WO2020205530A1 (en) 2019-03-29 2020-03-27 Liposomal formulations, and methods of using and preparing thereof

Publications (1)

Publication Number Publication Date
SG11202110623PA true SG11202110623PA (en) 2021-10-28

Family

ID=72666933

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202110623PA SG11202110623PA (en) 2019-03-29 2020-03-27 Liposomal formulations, and methods of using and preparing thereof

Country Status (19)

Country Link
US (1) US20220184107A1 (https=)
EP (1) EP3946365A4 (https=)
JP (1) JP7583741B2 (https=)
KR (1) KR20210143906A (https=)
CN (1) CN113873998A (https=)
AR (1) AR119705A1 (https=)
AU (1) AU2020252005B2 (https=)
BR (1) BR112021019593A2 (https=)
CA (1) CA3134828A1 (https=)
CL (1) CL2021002512A1 (https=)
CO (1) CO2021014274A2 (https=)
EA (1) EA202192663A1 (https=)
IL (1) IL286713B2 (https=)
MX (1) MX2021011876A (https=)
PE (1) PE20212366A1 (https=)
PH (1) PH12021552428A1 (https=)
SG (1) SG11202110623PA (https=)
TW (1) TWI906214B (https=)
WO (1) WO2020205530A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023205628A1 (en) * 2022-04-18 2023-10-26 City Of Hope Lipid nanoparticles, nucleic acids, and methods of use
TW202543582A (zh) * 2024-02-29 2025-11-16 美商葛里柯麥公司 脂質體調配物及其使用及製備方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1156783B1 (en) * 1999-03-02 2007-10-24 Transave, Inc. Encapsulation of bioactive complexes in liposomes
US7060291B1 (en) * 1999-11-24 2006-06-13 Transave, Inc. Modular targeted liposomal delivery system
WO2002076428A1 (en) * 2001-03-26 2002-10-03 Alza Corporation Liposome composition for improved intracellular delivery of a therapeutic agent
AU2003205048B2 (en) * 2002-01-09 2009-02-26 Transave, Inc. Efficient liposomal encapsulation
WO2003059322A1 (en) * 2002-01-09 2003-07-24 Elan Pharmaceuticals, Inc. Efficient nucleic acid encapsulation into medium sized liposomes
WO2010130896A2 (fr) * 2009-05-14 2010-11-18 Sanofi Pasteur Procédé pour adjuver le lipopolysaccharide (lps) des bactéries à gram-négatif
MX366055B (es) 2011-08-31 2019-06-26 Novartis Ag Liposomas pegilados para admistracion de acido ribonucleico (arn) que codifica para inmunogeno.
CA2890725A1 (en) 2012-11-05 2014-05-08 Pronai Therapeutics, Inc. Methods of using biomarkers for the treatment of cancer by modulation of bcl2|expression
DK3954360T3 (da) * 2013-09-16 2025-05-12 Glycomine Inc Farmaceutisk præparat af kulhydrater til terapeutisk anvendelse
JP2017537650A (ja) 2014-10-09 2017-12-21 ライポテック・ピーティーワイ・リミテッド キメラタンパク質
US20170165374A1 (en) * 2015-11-18 2017-06-15 Insmed, Inc. Compositions and methods for treating bacterial infections

Also Published As

Publication number Publication date
EP3946365A4 (en) 2023-04-19
CN113873998A (zh) 2021-12-31
AU2020252005A1 (en) 2021-11-04
JP2022527638A (ja) 2022-06-02
MX2021011876A (es) 2022-01-04
AR119705A1 (es) 2022-01-05
CL2021002512A1 (es) 2023-01-06
KR20210143906A (ko) 2021-11-29
AU2020252005B2 (en) 2025-11-27
CA3134828A1 (en) 2020-10-08
EP3946365A1 (en) 2022-02-09
JP7583741B2 (ja) 2024-11-14
EA202192663A1 (ru) 2022-03-01
TWI906214B (zh) 2025-12-01
US20220184107A1 (en) 2022-06-16
WO2020205530A1 (en) 2020-10-08
IL286713A (en) 2021-10-31
IL286713B1 (en) 2025-03-01
PE20212366A1 (es) 2021-12-21
IL286713B2 (en) 2025-07-01
BR112021019593A2 (pt) 2021-12-14
TW202102231A (zh) 2021-01-16
CO2021014274A2 (es) 2022-01-17
PH12021552428A1 (en) 2022-07-11

Similar Documents

Publication Publication Date Title
US20240082155A1 (en) Pharmaceutical preparation of carbohydrates for therapeutic use
SG11202110623PA (en) Liposomal formulations, and methods of using and preparing thereof
US10322087B2 (en) Targeted liposomal delivery of cGMP analogues
JPWO2014025042A1 (ja) 安定なオキサリプラチン封入リポソーム水分散液及びその安定化方法
US20080279916A1 (en) Liposome Preparation
AU2005247091B2 (en) Superloaded liposomes for drug delivery
EA050120B1 (ru) Липосомальные фармацевтические композиции и способ их применения
EP4108251A1 (en) Griffithsin for use in a method of preventing or treating infections with respiratory viruses
WO2025184395A1 (en) Methods of treating congenital disorders of glycosylation (cdg) and ataxia in subjects suffering from cdg
TW202543582A (zh) 脂質體調配物及其使用及製備方法
WO2020061670A1 (pt) Formulação lipossomal, composição farmacêutica, uso de uma formulação lipossomal, método para tratamento de câncer, e, processo para preparação de uma formulação lipossomal